<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01939028</url>
  </required_header>
  <id_info>
    <org_study_id>CASE9813</org_study_id>
    <secondary_id>NCI-2013-01309</secondary_id>
    <nct_id>NCT01939028</nct_id>
  </id_info>
  <brief_title>Lymph Node Mapping in Patients With Newly Diagnosed Endometrial Cancer Undergoing Surgery</brief_title>
  <official_title>Sentinel Lymph Node Mapping for Endometrial Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Case Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Case Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial studies lymph node mapping in patients with newly diagnosed endometrial&#xD;
      cancer undergoing surgery. Lymph node mapping may help in planning surgery to remove&#xD;
      endometrial cancer and affected lymph nodes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the detection rate, sensitivity, and negative predictive value of sentinel&#xD;
      lymph node (SLN) biopsy in endometrial cancer patients.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To compare different surgical modalities (open procedures, minimally invasive procedures,&#xD;
      and single-site technology) and different injectants (isosulfan blue and indocyanine green)&#xD;
      for SLN biopsy.&#xD;
&#xD;
      II. To determine total operating room time (from the time the patient enters the room to the&#xD;
      time the patient leaves the room) as well as console time (robotic)/operating time for&#xD;
      minimally invasive procedures.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients undergo SLN mapping using isosulfan blue and/or indocyanine green solution injected&#xD;
      directly into the cervix. Following SLN identification and biopsy, patients undergo&#xD;
      hysterectomy, bilateral salpingo-oophorectomy, and/or complete pelvic lymphadenectomy.&#xD;
      Patients expressing SLN positive for metastasis undergo para-aortic lymphadenectomy.&#xD;
&#xD;
      After completion of study treatment, patients are followed up at 2-4 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow Accrual&#xD;
  </why_stopped>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity of Sentential Lymph Node (SLN) Biopsy</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>Sensitivity estimated as the proportion of true positives among participants with lymph node metastases. Sensitivity Calculation= the number of patients with a positive SLN over those patients with a positive SLN plus those patients with a false negative lymph node.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants in Whom a SLN is Detected</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>Detection Rate as defined by number of participants in whom a SLN is detected</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent of Hemipelvises Identified With SLN</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>Detection rate, as defined by percent of hemipelvises identified with SLN</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Sentinel Nodes Per Side of Pelvis</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>Detection rate, as defined as number of participants with a sentinel node found per side of pelvis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>False Negative Rate as Defined as Proportion of Participants With False Negative Detection</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>False negative rate = 1-sensitivity or the number of patients with a false negative SLN over the number of patients with a positive SLN plus those with a false negative lymph node</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent of True Positive SLN Identified With Surgical Modalities (Open Procedures, Minimally Invasive Procedures, and Single-site Technology)</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>The percent of true positive SLN identified with surgical modalities using pairwise comparisons for each surgical modality. Comparisons will be performed using two sample tests of proportions based on a normal approximation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of True Positive SLNs Using Isosulfan Blue and Indocyanine Green Solution</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>Percent of true positive SLN identified will be compared between injectants utilized using a two sample test of proportions based on a normal approximation. Comparisons will be performed using two sample tests of proportions based on a normal approximation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Operating Room Time in Minutes</measure>
    <time_frame>From the time the patient enters the room to the time the patient leaves the room, assessed up to 4 weeks</time_frame>
    <description>Total operating room time will be estimated as a mean with 95% confidence interval if the data have an approximately normal distribution. Otherwise, the median and a bootstrapped 95% confidence interval for the median will be reported. Similar summaries will be provided for the console time (robotic)/ operating time.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Stage I Endometrial Carcinoma</condition>
  <condition>Stage II Endometrial Carcinoma</condition>
  <condition>Stage III Endometrial Carcinoma</condition>
  <condition>Stage IV Endometrial Carcinoma</condition>
  <arm_group>
    <arm_group_label>Diagnostic (SLN mapping, biopsy, surgery)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo SLN mapping using isosulfan blue and/or indocyanine green solution injected directly into the cervix. Following SLN identification and biopsy, patients undergo hysterectomy, bilateral salpingo-oophorectomy, and/or complete pelvic lymphadenectomy. Patients expressing SLN positive for metastasis undergo para-aortic lymphadenectomy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>lymph node mapping</intervention_name>
    <description>Undergo lymph node mapping using isosulfan blue and/or indocyanine green solution</description>
    <arm_group_label>Diagnostic (SLN mapping, biopsy, surgery)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>sentinel lymph node biopsy</intervention_name>
    <description>Undergo SLN biopsy</description>
    <arm_group_label>Diagnostic (SLN mapping, biopsy, surgery)</arm_group_label>
    <other_name>sentinel node biopsy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>isosulfan blue</intervention_name>
    <description>Undergo lymph node mapping using isosulfan blue and/or indocyanine green solution</description>
    <arm_group_label>Diagnostic (SLN mapping, biopsy, surgery)</arm_group_label>
    <other_name>Lymphazurin</other_name>
    <other_name>N-[4-[4-(diethylamino)phenyl] (2,5-disulfophenyl) Methylene]-2,5-cyclohexadien-1-ylidene]-N-ethylethanaminium hydroxide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>indocyanine green solution</intervention_name>
    <description>Undergo lymph node mapping using isosulfan blue and/or indocyanine green solution</description>
    <arm_group_label>Diagnostic (SLN mapping, biopsy, surgery)</arm_group_label>
    <other_name>IC-GREEN</other_name>
    <other_name>ICG solution</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>therapeutic conventional surgery</intervention_name>
    <description>Undergo hysterectomy, bilateral salpingo-oophorectomy and/or complete pelvic lymphadenectomy</description>
    <arm_group_label>Diagnostic (SLN mapping, biopsy, surgery)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>lymphadenectomy</intervention_name>
    <description>Undergo para-aortic lymphadenectomy</description>
    <arm_group_label>Diagnostic (SLN mapping, biopsy, surgery)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women must have newly diagnosed histologically or cytologically confirmed endometrial&#xD;
             cancer&#xD;
&#xD;
          -  Women should have received no prior therapy for their disease&#xD;
&#xD;
          -  Women who are planning to undergo hysterectomy, bilateral salpingo-oophorectomy, and&#xD;
             pelvic lymphadenectomy for the management of their endometrial cancer&#xD;
&#xD;
          -  Women must have the ability to understand and the willingness to sign a written&#xD;
             informed consent document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women who are receiving any other investigational agents&#xD;
&#xD;
          -  Women with a history of allergic reactions attributed to compounds of similar chemical&#xD;
             or biologic composition to isosulfan blue or indocyanine green or other agents used in&#xD;
             this study&#xD;
&#xD;
          -  Women with hypersensitivity to phenylmethane compounds, or a history of allergic&#xD;
             reaction to iodides&#xD;
&#xD;
          -  Patients with uncontrolled intercurrent illness including, but not limited to ongoing&#xD;
             or active infection, symptomatic congestive heart failure, unstable angina pectoris,&#xD;
             cardiac arrhythmia, or psychiatric illness/social situations that would limit&#xD;
             compliance with study requirements&#xD;
&#xD;
          -  Women with a history of prior loop electrosurgical excision procedure (LEEP) or cone&#xD;
             procedures performed on their cervix&#xD;
&#xD;
          -  Women with a history of lymphedema, lymphoma, or lymphatic hyperplasia (Castleman&#xD;
             disease)&#xD;
&#xD;
          -  Women with a history of a prior malignancy&#xD;
&#xD;
          -  Women may also be excluded at the discretion of their surgeon if he or she feels that&#xD;
             the patient is not an appropriate candidate&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chad Michener, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>July 10, 2013</study_first_submitted>
  <study_first_submitted_qc>September 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2013</study_first_posted>
  <results_first_submitted>July 30, 2020</results_first_submitted>
  <results_first_submitted_qc>July 30, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 17, 2020</results_first_posted>
  <last_update_submitted>August 26, 2020</last_update_submitted>
  <last_update_submitted_qc>August 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 2, 2013</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/28/NCT01939028/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 21, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/28/NCT01939028/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Diagnostic (SLN Mapping, Biopsy, Surgery)</title>
          <description>Patients undergo SLN mapping using isosulfan blue and/or indocyanine green solution injected directly into the cervix. Following SLN identification and biopsy, patients undergo hysterectomy, bilateral salpingo-oophorectomy, and/or complete pelvic lymphadenectomy. Patients expressing SLN positive for metastasis undergo para-aortic lymphadenectomy.&#xD;
lymph node mapping: Undergo lymph node mapping using isosulfan blue and/or indocyanine green solution&#xD;
sentinel lymph node biopsy: Undergo SLN biopsy&#xD;
isosulfan blue: Undergo lymph node mapping using isosulfan blue and/or indocyanine green solution&#xD;
indocyanine green solution: Undergo lymph node mapping using isosulfan blue and/or indocyanine green solution&#xD;
therapeutic conventional surgery: Undergo hysterectomy, bilateral salpingo-oophorectomy and/or complete pelvic lymphadenectomy&#xD;
lymphadenectomy: Undergo para-aortic lymphadenectomy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Evaluable participants who completed study</population>
      <group_list>
        <group group_id="B1">
          <title>Diagnostic (SLN Mapping, Biopsy, Surgery)</title>
          <description>Patients undergo SLN mapping using isosulfan blue and/or indocyanine green solution injected directly into the cervix. Following SLN identification and biopsy, patients undergo hysterectomy, bilateral salpingo-oophorectomy, and/or complete pelvic lymphadenectomy. Patients expressing SLN positive for metastasis undergo para-aortic lymphadenectomy.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="46"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>20-29 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30-39 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>40-49 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>50-59 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60-69 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>70-79 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>80-89 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Sensitivity of Sentential Lymph Node (SLN) Biopsy</title>
        <description>Sensitivity estimated as the proportion of true positives among participants with lymph node metastases. Sensitivity Calculation= the number of patients with a positive SLN over those patients with a positive SLN plus those patients with a false negative lymph node.</description>
        <time_frame>Up to 4 weeks</time_frame>
        <population>Participants with with lymph node metastases</population>
        <group_list>
          <group group_id="O1">
            <title>Diagnostic (SLN Mapping, Biopsy, Surgery)</title>
            <description>Participants undergo SLN mapping using isosulfan blue and/or indocyanine green solution injected directly into the cervix. Following SLN identification and biopsy, patients undergo hysterectomy, bilateral salpingo-oophorectomy, and/or complete pelvic lymphadenectomy. Patients expressing SLN positive for metastasis undergo para-aortic lymphadenectomy.</description>
          </group>
        </group_list>
        <measure>
          <title>Sensitivity of Sentential Lymph Node (SLN) Biopsy</title>
          <description>Sensitivity estimated as the proportion of true positives among participants with lymph node metastases. Sensitivity Calculation= the number of patients with a positive SLN over those patients with a positive SLN plus those patients with a false negative lymph node.</description>
          <population>Participants with with lymph node metastases</population>
          <units>percent</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants in Whom a SLN is Detected</title>
        <description>Detection Rate as defined by number of participants in whom a SLN is detected</description>
        <time_frame>Up to 4 weeks</time_frame>
        <population>Participants who completed study</population>
        <group_list>
          <group group_id="O1">
            <title>Diagnostic (SLN Mapping, Biopsy, Surgery)</title>
            <description>Participants undergo SLN mapping using isosulfan blue and/or indocyanine green solution injected directly into the cervix. Following SLN identification and biopsy, patients undergo hysterectomy, bilateral salpingo-oophorectomy, and/or complete pelvic lymphadenectomy. Patients expressing SLN positive for metastasis undergo para-aortic lymphadenectomy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants in Whom a SLN is Detected</title>
          <description>Detection Rate as defined by number of participants in whom a SLN is detected</description>
          <population>Participants who completed study</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent of Hemipelvises Identified With SLN</title>
        <description>Detection rate, as defined by percent of hemipelvises identified with SLN</description>
        <time_frame>Up to 4 weeks</time_frame>
        <population>Participants who completed study</population>
        <group_list>
          <group group_id="O1">
            <title>Diagnostic (SLN Mapping, Biopsy, Surgery)</title>
            <description>Participants undergo SLN mapping using isosulfan blue and/or indocyanine green solution injected directly into the cervix. Following SLN identification and biopsy, patients undergo hysterectomy, bilateral salpingo-oophorectomy, and/or complete pelvic lymphadenectomy. Patients expressing SLN positive for metastasis undergo para-aortic lymphadenectomy.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Hemipelvises Identified With SLN</title>
          <description>Detection rate, as defined by percent of hemipelvises identified with SLN</description>
          <population>Participants who completed study</population>
          <units>Percent of Hemipelvises</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Sentinel Nodes Per Side of Pelvis</title>
        <description>Detection rate, as defined as number of participants with a sentinel node found per side of pelvis</description>
        <time_frame>Up to 4 weeks</time_frame>
        <population>Participants who completed study</population>
        <group_list>
          <group group_id="O1">
            <title>Diagnostic (SLN Mapping, Biopsy, Surgery)</title>
            <description>Participants undergo SLN mapping using isosulfan blue and/or indocyanine green solution injected directly into the cervix. Following SLN identification and biopsy, patients undergo hysterectomy, bilateral salpingo-oophorectomy, and/or complete pelvic lymphadenectomy. Patients expressing SLN positive for metastasis undergo para-aortic lymphadenectomy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Sentinel Nodes Per Side of Pelvis</title>
          <description>Detection rate, as defined as number of participants with a sentinel node found per side of pelvis</description>
          <population>Participants who completed study</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Right side of pelvis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left side of pelvis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>False Negative Rate as Defined as Proportion of Participants With False Negative Detection</title>
        <description>False negative rate = 1-sensitivity or the number of patients with a false negative SLN over the number of patients with a positive SLN plus those with a false negative lymph node</description>
        <time_frame>Up to 4 weeks</time_frame>
        <population>Participants who completed study</population>
        <group_list>
          <group group_id="O1">
            <title>Diagnostic (SLN Mapping, Biopsy, Surgery)</title>
            <description>Participants undergo SLN mapping using isosulfan blue and/or indocyanine green solution injected directly into the cervix. Following SLN identification and biopsy, patients undergo hysterectomy, bilateral salpingo-oophorectomy, and/or complete pelvic lymphadenectomy. Patients expressing SLN positive for metastasis undergo para-aortic lymphadenectomy.</description>
          </group>
        </group_list>
        <measure>
          <title>False Negative Rate as Defined as Proportion of Participants With False Negative Detection</title>
          <description>False negative rate = 1-sensitivity or the number of patients with a false negative SLN over the number of patients with a positive SLN plus those with a false negative lymph node</description>
          <population>Participants who completed study</population>
          <units>Proportion of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent of True Positive SLN Identified With Surgical Modalities (Open Procedures, Minimally Invasive Procedures, and Single-site Technology)</title>
        <description>The percent of true positive SLN identified with surgical modalities using pairwise comparisons for each surgical modality. Comparisons will be performed using two sample tests of proportions based on a normal approximation.</description>
        <time_frame>Up to 4 weeks</time_frame>
        <population>Participants who completed study</population>
        <group_list>
          <group group_id="O1">
            <title>Diagnostic (SLN Mapping, Biopsy, Surgery)</title>
            <description>Participants undergo SLN mapping using isosulfan blue and/or indocyanine green solution injected directly into the cervix. Following SLN identification and biopsy, patients undergo hysterectomy, bilateral salpingo-oophorectomy, and/or complete pelvic lymphadenectomy. Patients expressing SLN positive for metastasis undergo para-aortic lymphadenectomy.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of True Positive SLN Identified With Surgical Modalities (Open Procedures, Minimally Invasive Procedures, and Single-site Technology)</title>
          <description>The percent of true positive SLN identified with surgical modalities using pairwise comparisons for each surgical modality. Comparisons will be performed using two sample tests of proportions based on a normal approximation.</description>
          <population>Participants who completed study</population>
          <units>percentage of true positive SNLs</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Laparoscopy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Robot</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Single port</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of True Positive SLNs Using Isosulfan Blue and Indocyanine Green Solution</title>
        <description>Percent of true positive SLN identified will be compared between injectants utilized using a two sample test of proportions based on a normal approximation. Comparisons will be performed using two sample tests of proportions based on a normal approximation.</description>
        <time_frame>Up to 4 weeks</time_frame>
        <population>Participants who completed study</population>
        <group_list>
          <group group_id="O1">
            <title>Diagnostic (SLN Mapping, Biopsy, Surgery)</title>
            <description>Participants undergo SLN mapping using isosulfan blue and/or indocyanine green solution injected directly into the cervix. Following SLN identification and biopsy, patients undergo hysterectomy, bilateral salpingo-oophorectomy, and/or complete pelvic lymphadenectomy. Patients expressing SLN positive for metastasis undergo para-aortic lymphadenectomy.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of True Positive SLNs Using Isosulfan Blue and Indocyanine Green Solution</title>
          <description>Percent of true positive SLN identified will be compared between injectants utilized using a two sample test of proportions based on a normal approximation. Comparisons will be performed using two sample tests of proportions based on a normal approximation.</description>
          <population>Participants who completed study</population>
          <units>Percentage of true positive SLNs</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>indocyanine green</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blue dye</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Operating Room Time in Minutes</title>
        <description>Total operating room time will be estimated as a mean with 95% confidence interval if the data have an approximately normal distribution. Otherwise, the median and a bootstrapped 95% confidence interval for the median will be reported. Similar summaries will be provided for the console time (robotic)/ operating time.</description>
        <time_frame>From the time the patient enters the room to the time the patient leaves the room, assessed up to 4 weeks</time_frame>
        <population>Participants who completed study</population>
        <group_list>
          <group group_id="O1">
            <title>Diagnostic (SLN Mapping, Biopsy, Surgery)</title>
            <description>Participants undergo SLN mapping using isosulfan blue and/or indocyanine green solution injected directly into the cervix. Following SLN identification and biopsy, patients undergo hysterectomy, bilateral salpingo-oophorectomy, and/or complete pelvic lymphadenectomy. Patients expressing SLN positive for metastasis undergo para-aortic lymphadenectomy.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Operating Room Time in Minutes</title>
          <description>Total operating room time will be estimated as a mean with 95% confidence interval if the data have an approximately normal distribution. Otherwise, the median and a bootstrapped 95% confidence interval for the median will be reported. Similar summaries will be provided for the console time (robotic)/ operating time.</description>
          <population>Participants who completed study</population>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158.5" lower_limit="138.91" upper_limit="178.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 30 days from last treatment dose</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Diagnostic (SLN Mapping, Biopsy, Surgery)</title>
          <description>Patients undergo SLN mapping using isosulfan blue and/or indocyanine green solution injected directly into the cervix. Following SLN identification and biopsy, patients undergo hysterectomy, bilateral salpingo-oophorectomy, and/or complete pelvic lymphadenectomy. Patients expressing SLN positive for metastasis undergo para-aortic lymphadenectomy.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE v4.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>New onset atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Chad Michener</name_or_title>
      <organization>University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center</organization>
      <phone>216-444-6601</phone>
      <email>michenc@ccf.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

